CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 9 No. 8
 

Book Review: Cambridge Medical Reviews--Haematologic Oncology, Volume 3

By

Editors: Allen Burnett, James Armitage, Adrian Newland, and Armand Keating
Publisher: Cambridge U Press
Pages: 248
Price: $89.95

Reviewed by:Mark Weiss, MD
Memorial Sloan-Kettering Cancer Center, New York

| August 1, 1995


Volume 3 of Cambridge Medical Reviews: Haematologic Oncology provides detailed reviews on 10 topics of current interest in the field of hematologic malignancies. The text is organized into 10 chapters and has 22 contributors.

The initial chapter, on the epidemiology of non-Hodgkin's lymphoma, is a compendium of epidemiologic data from multiple sources. The strength of this chapter resides predominantly in the six tables used to summarize the epidemiologic data. This tabulation will provide a useful reference for anyone requiring worldwide epidemiologic data on these diseases.

The second chapter, authored by David Onions, is a brief introduction to the role of viruses as etiologic agents of leukemia and lymphoma. This discussion is well written and easily comprehensible to the practicing oncologist.

The third chapter on bone marrow stroma microenvironment, by M.I. Gordon, acts as a basic introduction to this complex, yet relatively poorly understood, area of hematopoiesis.

The fourth chapter is an analysis of treatment for multiple myeloma, with an emphasis on the Medical Research Council (MRC) trials. While the discussion of the literature as a whole puts many issues into proper perspective, the emphasis on the MRC trials, which are listed by their sequential numbers, is somewhat confusing and detracts from the readability of this text. The chapter would have been more valuable for the practicing oncologist if it had presented an overall review of chemotherapy for multiple myeloma, rather than emphasizing the more general results in comparison to the MRC trials.

The fifth chapter, by D. Samsom, reviews the field of bone marrow transplantation for multiple myeloma. It discusses separately the use of allogeneic, syngeneic, and autologous transplants. It also explores important issues, including the graft-vs-myeloma effect and the use of dose-intensification regimens. The chapter is well organized, and while written from a dose-intensification perspective, points out that the final answer about the value of autologous transplantation vs chemotherapy is not yet in.

The sixth chapter, on peripheral blood stem cells for therapeutic use, is written by C.A. Juttner and L.B. To. This chapter describes both the theoretical and practical advantages of peripheral stem-cell transplantation, and illustrates the advantage of peripheral progenitor transplants over marrow-based transplants.

The seventh chapter, written by D.J. Culligan and A.K. Burnett, is entitled "The Laboratory Aspects of Myelodysplasia." This chapter starts with the morphologic definitions of the myelodysplastic syndromes, as determined by the French-American-British (FAB) Group in 1982. It then discusses the impact of cytogenetics, immunohistochemistry, immunophenotyping, progenitor growth studies, and molecular biologic analysis on this field. This chapter helps the clinician understand these modern advances, in particular, how these tools allow for a better understanding of the pathophysiology of these diseases when compared to morphologic analysis alone.

The eighth chapter, authored by C. Chomienne et al, is a brief discussion of one of the most exciting treatment results in oncology over the last decade--the use of retinoids in acute promyelocytic leukemia. This group's discussion of the clinical activity of retinoids in this disease is relatively brief, and includes a hypothesis of how retinoic acid induces complete responses in patients with acute promyelocytic leukemia.

The ninth chapter, on the cytogenetics of acute lymphoblastic leukemia, is a useful introduction to this very confusing field. Table I is a useful summary of the more important chromosomal abnormalities seen in this disease. Unfortunately, both the table's overall layout and use of abbreviations make it difficult to read.

The final chapter, on fungal infections complicating hematologic malignancies, is a useful review of this area for the practicing oncologist. This chapter is practical in its approach, in that it avoids the often confusing, detailed listing of all possible fungal infections seen in such patients. Rather, it focuses on the most common agents and the best approaches for treating infections caused by these pathogens.

Overall, the third volume of Haematologic Oncology is filled with a variety of informative chapters for the practicing physician. In general, the information is presented in a fashion that should be useful to the treating oncologist. One drawback is that the topics chosen are quite diverse, which disrupts the organization of this text.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

A 48-Year-Old Woman With Irregular Vaginal Bleeding
Brian Morse, MD1 , June 10, 2013

A 48-year-old female presents with complaints of irregular vaginal bleeding and postcoital bleeding. Images from a PET/CT and pelvis MRI reveal characteristic findings. What is your diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
  • ASCO: PD-L1 Antibody Elicits Durable Response in RCC
  • RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • Radiation-Induced Enteritis: Incidence, Mechanisms, and Management
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy